Solara Active Pharma zooms after reporting turnaround Q2 PAT to Rs 28 cr
The company reported a profit before tax of Rs 28.46 crore in Q2 FY27, compared with a loss before tax of Rs 10.10 crore in the corresponding quarter of the previous financial year.
EBITDA rose 21% YoY to Rs 76.9 crore in Q2 FY27, while the EBITDA margin improved to 18.4% from 11.2% in Q2 FY26.
Base business revenue increased 37% YoY to Rs 327.3 crore, while ibuprofen revenue grew 21% YoY to Rs 90.5 crore.
Sandeep Rao, managing director (MD), CEO, said, ?Our Base business continues to lead our growth. Revenue grew 37% to INR 3,273 Mn, staying above INR 3,000 Mn for the third quarter in a row, and EBITDA grew 68% to INR 771 Mn, with the margin up about 440 bps to 23.6% even as raw material costs rose.
Ibuprofen is turning around. Revenue grew 21% over last year and 18% over last quarter, and the business is now close to breakeven, from a loss margin of 21% just two quarters ago. As a result, overall revenue grew 33% to Rs 417.8 crore and EBITDA more than doubled, up 118% to Rs 76.9 crore. We are firmly back in profit, with PAT of Rs 28.5 crore against a loss of Rs 10.1 crore a year ago. Net debt to EBITDA is down to about 1.8x from 3.2x at the end of FY26, giving us room to keep investing in growth.?
Solara Active Pharma Sciences is a pure play global API manufacturer supported by R&D and manufacturing facilities.
Powered by Capital Market - Live News